Leptin Gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents

Psychiatric Genetics

Volumn 19, Issue 6, 2009, Pages 320-327

  Calarge, Chadi A ^a   Ellingrod, Vicki L ^c   Zimmerman, Bridget ^b   Acion, Laura ^a   Sivitz, William I ^a   Schlechte, Janet A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Biostatistics ^*

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adolescents; Antipsychotics; Children; Leptin gene; Predictors; Variants; Weight gain

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEPTIN; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENCE; ADOLESCENT; ALLELE; ANAMNESIS; ANTHROPOMETRY; ARTICLE; BEHAVIOR DISORDER; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CHILD; CONCENTRATION (PARAMETERS); FEMALE; GENETIC VARIABILITY; GENOTYPE; GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBESITY; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; CHILD; DNA PRIMERS; FEMALE; HUMANS; LEPTIN; MALE; POLYMERASE CHAIN REACTION; RISPERIDONE; WEIGHT GAIN;

EID: 70350761776     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e3283328e06     Document Type: Article

References (49)

1. ADA (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
3. Aman MG, Binder C, Turgay A (2004). Risperidone effects in the presence/ absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243-254.
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346.
5. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, et al. (2007). Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545-550.
6. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, Text Revision. Washington, DC: American Psychiatric Association.
7. Baptista T, Davila A, El Fakih Y, Uzcategui E, Rangel NN, Olivares Y, et al. (2007). Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 22:205-211.
8. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Muller J, et al. (1997). Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 82:2904-2910.
9. Calarge CA, Acion L, Kuperman S, Tansey MJ, Schlechte JA (2009). Metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19:101-109.
10. CDC (2000). National Health and Nutrition Examination Survey: anthropometry Procedures Manual (Revised December 2000).
11. Cole D, Calarge CA, Ellingrod VL, Schlechte JA (2008). Effect of the - 759C/T variants of the serotonin (5-HT2C) receptor gene on risperidone- associated weight gain in children and adolescents in extended treatment. Chicago, Illinois: American Academy of Child and Adolescent Psychiatry.
12. Correll CU, Carlson HE (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791.
13. Correll CU, Nyilas M, Aurang C, Johnson B, Jin N, Marcus R, et al. (2007). Longterm safety and tolerability of aripiprazole in children (10-17) with mania. Boston, Massachusetts: American Academy of Child and Adolescent Psychiatry.
14. Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller del D (2007). Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 40:57-62.
15. Friedman JM (1997). The alphabet of weight control. Nature 385:119-120.
16. Gregoor JG, van der Weide J, Mulder H, Cohen D, van Megen HJ, Egberts AC, Heerdink ER (2009). Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 29:21-25.
17. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW (2005). Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 30:184-191.
18. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P (2002). A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 34:355-359.
19. Kang SG, Lee HJ, Park YM, Choi JE, Han C, Kim YK, et al. (2008). Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32:160-163.
20. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007). From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104:3456-3459.
21. Le Stunff C, Le Bihan C, Schork NJ, Bougneres P (2000). A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes 49:2196-2200.
22. Mammes O, Betoulle D, Aubert R, Giraud V, Tuzet S, Petiet A, et al. (1998). Novel polymorphisms in the 50 region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes 47:487-489.
23. Mammes O, Betoulle D, Aubert R, Herbeth B, Siest G, Fumeron F (2000). Association of the G-2548A polymorphism in the 50 region of the LEP gene with overweight. Ann Hum Genet 64:391-394.
24. Mansoub S, Chan MK, Adeli K (2006). Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome. Clin Biochem 39:569-587.
25. Marshall WA, Tanner JM (1969). Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291-303.
26. Marshall WA, Tanner JM (1970). Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23.
27. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006). Central nervous system control of food intake and body weight. Nature 443:289-295.
28. MTA cooperative group (2004). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113:762-769.
29. Newcomer JW, Haupt DW (2006). The metabolic effects of antipsychotic medications. Can J Psychiatry 51:480-491.
30. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, et al. (2002). Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60.
31. Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685.
32. Poulton A (2005). Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 90:801-806.
33. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39.
34. Ronaghi M (2003). Pyrosequencing for SNP genotyping. Methods Mol Biol 212:189-195.
35. Ruano G, Goethe JW, Caley C,Woolley S, Holford TR, Kocherla M, et al. (2007). Physiogenomic comparison of weight profiles of olanzapine- and risperidonetreated patients. Mol Psychiatry 12:474-482.
36. Scarpace PJ, Zhang Y (2007). Elevated leptin: consequence or cause of obesity? Front Biosci 12:3531-3544.
37. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000). Central nervous system control of food intake. Nature 404:661-671.
38. Sivitz WI, Wayson SM, Bayless ML, Larson LF, Sinkey C, Bar RS, Haynes WG (2003). Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 88:1543-1553.
39. Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, Van Loan MD, Bemben DA (1988). Skinfold equations for estimation of body fatness in children and youth. Hum Biol 60:709-723.
40. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036.
41. Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, et al. (2006). Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45:1304-1313.
42. Swanson JM, Elliott GR, Greenhill LL,Wigal T, Arnold LE, Vitiello B, et al. (2007). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46:1015-1027.
43. Templeman LA, Reynolds GP, Arranz B, San L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic druginduced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195-200.
44. Unger RH (2003). The physiology of cellular liporegulation. Annu Rev Physiol 65:333-347.
45. Van der Lende T, Te Pas MF, Veerkamp RF, Liefers SC (2005). Leptin gene polymorphisms and their phenotypic associations. Vitam Horm 71:373-404.
46. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S (2002). Body weight changes associated with psychopharmacology. Psychiatr Serv 53:842-847.
47. Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D, Mantzoros CS (2001). The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J Clin Endocrinol Metab 86: 4434-4439.
48. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, et al. (2007). Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 27:246-251.
49. Zhang ZJ, Yao ZJ, Mou XD, Chen JF, Zhu RX, Liu W, et al. (2003). Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Zhonghua Yi Xue Za Zhi 83:2119-2123.